Merger of drugmakers Valeant, Actavis on hold: source
(Reuters) – A proposed merger of Valeant Pharmaceuticals International Inc and Actavis Inc was put on hold after the two drugmakers failed to agree on terms of a deal that would have created a healthcare giant with a combined market value of $35 billion, a person familiar with the situation told Reuters on Saturday. Actavis spokesman David Belian and Valeant spokeswoman Laurie Little both declined to comment. Canada’s Valeant was seeking to buy smaller U. S. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply